BofA analyst Kevin Fischbeck raised the firm’s price target on Humana to $376 from $342 and keeps a Neutral rating on the shares. The firm cites a higher multiple given the positive data points in its Trend Tracker along with the company’s commentary at BofA’s conference that trend is coming in slightly better than expected for a higher price target, but reiterates a Neutral rating as it sees the value in Humana’s platform over the long-term being offset by short-term headwinds.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HUM:
- Starboard Value buys Alight, cuts Humana in Q1
- Humana first commercial payer to address TMS Therapy coverage for adolescents
- Humana saw ‘some incremental positivity’ as claims further matured
- Humana Inc. Announces CEO Transition and Advisory Role Shifts
- Third Point lists Meta, Amazon among Q1 winners, starts position in Advance Auto
